NEW YORK (GenomeWeb News) – Biovista today announced its European Union affiliate has been awarded a $500,000 grant to apply its technology to an EU project in personalized medicine.
The grant will be used by the firm to apply the multi-dimensional profiling capabilities of its Clinical Outcomes Search Space platform to identify new treatments "that reflect patients' individual pathophysiological characteristics," it said.
The EU project, called "p-medicine," is a four-year €13.3 million ($19.4 million) co-funded initiative under the EU's 7th Framework Programme, and aims to develop new tools, infrastructure, and virtual physiological human models to hasten personalized medicine.
The technical manager on "p-medicine" is Norbert Graf, director of the Clinic for Pediatric Oncology and Hematology of the University Clinic of Saarland, Germany, where the area of specific interest is in Wilms tumor, the most common kidney cancer in children. Work will be directed at the development of potential biomarkers identified by Biovista for the disease, he said.
"While significant advances have been achieved in the last few years, we are still facing challenges in the areas of resistant disease to conventional chemotherapy where new and intelligent approaches are needed," he said in a statement.
Biovista is based in Charlottesville, Va., with its EU affiliate headquartered in Athens, Greece, and develops customized disease-treatment approaches as well as new uses for existing drugs. It is developing a drug pipeline in multiple indications and is "collaborating" with the US Food and Drug Administration on the prediction of adverse events, it said.